Robert C. Doebele, MD, PhD, shares his thoughts on what the next steps are for entrectinib in patients with <em>ROS1</em>-positive non–small cell lung cancer. In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are <em>ROS1</em>-positive.
Robert C. Doebele, MD, PhD, an associate professor in the Division of Medical Oncology at the School of Medicine, University of Colorado, shares his thoughts on what the next steps are for entrectinib (Rozlytrek) in patients withROS1-positive nonsmall cell lung cancer (NSCLC). In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who areROS1-positive.
Understanding the mechanisms of resistance to entrectinib is an important next step, says Doebele. Next-generation drugs are being evaluated following failure with entrectinib, such as agents like repotrectinib (TPX-0005). However, understanding the types of resistance we see with entrectinib may further help us understand which drug should follow entrectinib. Doebele says that having new therapies for patients who fail first-line therapies is 1 of the goals in among oncologists who specialize in lung cancer.
In August 2019, entrectinib also received an accelerated approval from the FDA for the treatment of adult and adolescent patients with solid tumors harboring anNRTKgene fusion who have no alternative therapies available. For more information on these approvals of entrectinib: https://www.targetedonc.com/news/fda-approves-entrectinib-for-ros1-nsclc-and-ntrk-solid-tumors
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More